Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Oncobit AG logo — Enabling personalized cancer care

Oncobit AG

Enabling personalized cancer care

Founded 2018 Switzerland Schlieren, Switzerland 15 employees Seed Total: $2.45M Biotechnology, Health Care

General Information

Company Name Oncobit AG
Founded Year 2018
Location Switzerland Schlieren, Switzerland
Employees 15
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, D2C, B2D
Revenue Model Service Fee, Licensing, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Oncobit AG. To contact Oncobit AG, visit oncobit.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Oncobit AG compare?

A PDF of Oncobit AG and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Oncobit AG soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Oncobit AG

Oncobit AG, with its slogan "Enabling personalized cancer care," is a promising player in the medtech space, operating at the intersection of Biotechnology and Health Care. Founded in 2018 as a UZH Spin-off, the company is based in Switzerland. Its core mission involves developing cancer-specific genomic fingerprinting and personalized monitoring tests to enhance therapy decision support for personalized cancer care.

The company gained traction by attracting a Fr.150.00K Seed Round investment on 21 January 2022, with backing from Venture Kick. This financial boost underscores confidence in Oncobit's potential to innovate cancer treatment personalization, leveraging cutting-edge genomic methodologies. As the demand for individualized healthcare solutions grows, Oncobit's strategic focus positions it as a venture worth watching for potential investors eyeing advancements in oncology and personalized medicine.

Business keywords: personalized cancer care, medtech, genomic fingerprinting, personalized monitoring tests, therapy decision support, diagnostic tests, cancer treatment matching, UZH Spin-off, cancer-specific diagnostics, precision medicine, cancer genomics, oncology solutions

Services & Products

High-precision cancer monitoring solutions
Personalized cancer care
Therapy-decision support
Innovative cancer-specific monitoring tests

Target Customers

Physicians Clinicians Oncology Diagnostics Companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Fr.150.00K 1
Venture Kick
Venture Kick
21 Jan 2022
Seed Round Fr.2.30M 2
GF Group Holding
GF Group Holding, AVANTECA Partners
30 Apr 2021

Oncobit AG Alternatives & Competitors

View All Alternatives
Oncobit AG vs
Cvergenx
Cvergenx United States

An innovative leader in cancer molecular diagnostics, delivering personalized radiation therapy to e...

Seed
2 employees
Biotechnology, Health Care
Compare Oncobit AG vs Cvergenx
Oncobit AG vs
ACT Genomics
ACT Genomics Taiwan

Make Personalized Medicine Accessible To All.

Venture round
121 employees
Biotechnology, Health Care
Oncobit AG vs
MiraDx
MiraDx United States

Tailoring cancer treatment based on your patient’s unique response and toxicity profile.

Series A
28 employees
Biotechnology, Health Care
Also compare with: Oncobit AG vs Guardant Health Guardant Health View all alternatives

FAQ About Oncobit AG

Enabling personalized cancer care
Oncobit AG was founded in 2018.
Oncobit AG is headquartered in Schlieren, Switzerland.
Oncobit AG operates in Biotechnology and Health Care. Its work centres on personalized cancer care, medtech, genomic fingerprinting and personalized monitoring tests. Its customers include Physicians, Clinicians and Oncology Diagnostics Companies.
Oncobit AG has a B2B, D2C and B2D business model. Its revenue comes from Service Fee, Licensing and Usage Based.
Oncobit AG has approximately 15 employees.
Oncobit AG has completed 2 funding rounds, raising a total of $2.45M. The latest funding stage is Seed.
Oncobit AG offers: High-precision cancer monitoring solutions, Personalized cancer care, Therapy-decision support, Innovative cancer-specific monitoring tests.
Top alternatives and competitors to Oncobit AG include Cvergenx, ACT Genomics, MiraDx, OncoDNA, Agendia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Oncobit AG and Cvergenx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Oncobit AG, https://bouncewatch.com/company/oncobit-ag, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes